

Delphi Genetics Announces an Investment of more than €3 million in the Charleroi Aeropole Business Park

*An investment in a building
dedicated to its own research and production*

Shanghai, China: 25 June 2010 - On Walloon Biotech Day organised at the Shanghai World Fair, in the Belgian Pavilion, [Delphi Genetics](#) announced its decision today to invest €3.5 million in a building that will be entirely dedicated to its activity. This 1500m² building will house the company's Research & Development Department, its service activities and the manufacturing of its products. Since July 2006, Delphi Genetics has been renting an area of 450 square metres in Igretec's bridging building in the Charleroi Aeropole Business Park near the Institute of Biology and Molecular Medicine (IBM) of the Université Libre de Bruxelles (ULB). The new building, the inauguration of which is envisaged for 2012, will be located in the ULB's Biopark, which already contains several Biotech companies.

Dr Cédric Szpirer, Chief Executive Officer of Delphi Genetics and one of its founders, explained: *"Delphi Genetics' business is growing: we have more and more contacts with major companies in the biopharmacy and biotechnology fields. These contacts lead to new licensing agreements or partnerships and result in increased activity in terms of services and production alike. We also have several research projects underway. We therefore need more space to achieve our objectives. The new building will enable us to accommodate up to 45 people and an extension will be possible should it prove to be necessary."*

In June 2009, Delphi Genetics announced a licensing agreement with Sanofi-Pasteur, Sanofi-Aventis's human vaccines division. This agreement enables Sanofi-Pasteur to implement the StabyExpress technology in its production of recombinant vaccines and therefore to be able to produce them efficiently without using antibiotic markers.

About Delphi Genetics SA

Founded at the end of 2001, [Delphi Genetics](#) develops more effective products and technologies for genetic engineering and for protein expression in bacteria by using its unique expertise in the field of plasmid stabilisation systems. Delphi Genetics' patented [Staby®](#) technology increases the recombinant protein production output without the use of antibiotics, which is the traditional approach. For further information, please visit our website: <http://www.delphigenetics.com>.

Contact for Delphi Genetics SA

delphigenetics@delphigenetics.com

Tel: +32 71 25 10 00



